Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from China Resources Pharmaceutical Group Ltd. ( (HK:3320) ).
China Resources Pharmaceutical Group Ltd. has entered into the Amended Business Travel Services Framework Agreement 2026 with CR Digital, a wholly-owned subsidiary of its controlling shareholder, CRI. This agreement, effective from December 10, 2025, to December 31, 2027, replaces the previous 2025 agreement and outlines the use of CR Digital’s online business travel platform for various services. The transactions under this agreement are classified as continuing connected transactions, requiring reporting and annual review but exempt from independent shareholders’ approval due to their percentage ratios.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
Average Trading Volume: 15,366,756
Technical Sentiment Signal: Sell
Current Market Cap: HK$29.34B
See more insights into 3320 stock on TipRanks’ Stock Analysis page.